Document Detail


Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications.
MedLine Citation:
PMID:  12756077     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Estrogen-targeted therapies such as administration of tamoxifen or aromatase inhibitors are among the most important treatment strategies in the modern management of breast cancer. Despite initial responses in the metastatic setting and prolonged disease-free intervals in the adjuvant setting, many patients subsequently become resistant to these agents. Human epidermal growth factor receptor-2 (HER2) is a transmembrane glycoprotein receptor that is overexpressed in 13%-30% of human breast cancers. There are experimental data suggesting an important role for HER2 in de novo and acquired resistance to endocrine therapies. These experimental data are discussed in this article, as are clinical data addressing the role of HER2 in resistance to endocrine therapy in the adjuvant, neoadjuvant, and metastatic settings. Responses and benefit from tamoxifen appear to be impaired in patients in whom HER2 is overexpressed. In contrast, early data from the neoadjuvant setting suggest that responses to aromatase inhibitors may be maintained in patients with HER2 overexpression.
Authors:
Alistair Ring; Mitch Dowsett
Related Documents :
12867067 - Integration of the proteasome inhibitor ps-341 (velcade) into the therapeutic approach ...
9703907 - Keratinocyte growth factor (kgf) induces aromatase activity in cultured mcf-7 human bre...
21547577 - Gene copy number variation in male breast cancer by acgh.
18254777 - Egfr expression in urothelial carcinoma of the upper urinary tract is associated with d...
11091657 - Biological effects of heavy ion beam on human breast cancers.
8739077 - Regularity and length of menstrual cycles in women aged 41-46 in relation to breast can...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical breast cancer     Volume:  4 Suppl 1     ISSN:  1526-8209     ISO Abbreviation:  Clin. Breast Cancer     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-05-20     Completed Date:  2005-11-22     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  100898731     Medline TA:  Clin Breast Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S34-41     Citation Subset:  IM    
Affiliation:
Department of Academic Biochemistry, Wallace Wing, Royal Marsden Hospital, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Hormonal / pharmacology*,  therapeutic use
Aromatase Inhibitors / pharmacology*,  therapeutic use
Breast Neoplasms / drug therapy*,  metabolism
Chemotherapy, Adjuvant
Drug Resistance, Neoplasm / drug effects
Female
Humans
Neoadjuvant Therapy
Randomized Controlled Trials as Topic
Receptor, Epidermal Growth Factor / drug effects,  metabolism*
Receptor, erbB-2 / drug effects,  metabolism*
Receptors, Estrogen / drug effects
Survival Analysis
Tamoxifen / pharmacology*,  therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Aromatase Inhibitors; 0/Receptors, Estrogen; 10540-29-1/Tamoxifen; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast canc...
Next Document:  Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.